Type 2 diabetes mellitus is a growing global public health problem, the prevalence of which
is projected to increase in the succeeding decades. It is potentially associated with many …

Clinical trials with sodium–glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin,
dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic …

Abstract Sodium glucose cotransporter 2 (SGLT2) inhibitors are beneficial in halting diabetic
kidney disease; however, the complete mechanisms have not yet been elucidated. The …

Abstract Dipeptidyl peptidase-4 inhibitor (vildagliptin) has been shown to exert beneficial
effects on insulin sensitivity and neuroprotection in obese-insulin resistance. Recent studies …

Background: The prevalence of type 2 diabetes (DM) in children is disturbingly increasing in
parallel with the increasing childhood obesity. Better knowledge regarding the …

Diabetes mellitus is a disease that affects millions of people worldwide and its prevalence is
estimated to rise in the future. Billions of dollars are spent each year around the world in …

An increasing array of anti-diabetic drugs are available today, yet Type-2 diabetes mellitus
(T2DM)–remains a life threatening disease, causing high mortality and morbidity in …

Kidneys play an important role in glucose homeostasis. Renal gluconeogenesis prevents
hypoglycemia by releasing glucose into the blood stream. Glucose homeostasis is also due …

Purpose of Review Type 2 diabetes mellitus (T2DM) is a prevalent disease with the severe
clinical implications including myocardial infarction, stroke, and kidney disease. Therapies …

Diabetes is a chronic progressive metabolic disease caused by insulin deficiency or insulin
resistance. In spite of the availability of several antihyperglycaemics, there is a need for the …